APOL1 testing in clinical practice and opportunities for new therapies
Mechanisms of APOL1 risk variant nephrotoxicity remain unclear; nonetheless, specific therapies for AMKD show great promise and may improve understanding of disease processes. With ongoing clinical trials and the potential for effective AMKD treatments, more widespread APOL1 genotyping will likely be needed.
Authors
- B. I. Freedman
- Taewoo Lee (ORCID: https://orcid.org/0000-0003-1720-2672)
- Lijun Ma (ORCID: https://orcid.org/0000-0002-7763-7793)
Institutions
- Wake Forest University (US)
Publication Details
- Journal
- Current Opinion in Nephrology & Hypertension
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1097/mnh.0000000000001082
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00